Short Interest in Carisma Therapeutics, Inc. (NASDAQ:CARM) Drops By 16.5%

Carisma Therapeutics, Inc. (NASDAQ:CARM) saw a large decrease in short interest in February. As of February 15th, there was short interest totalling 596,500 shares, a decrease of 16.5% from the January 31st total of 714,400 shares. Approximately 2.9% of the company’s stock are short sold. Based on an average daily volume of 358,800 shares, the short-interest ratio is currently 1.7 days.

Carisma Therapeutics Trading Up 2.0 %

NASDAQ CARM traded up $0.01 on Thursday, hitting $0.41. 113,192 shares of the stock were exchanged, compared to its average volume of 335,403. The company’s 50-day moving average price is $0.46 and its two-hundred day moving average price is $0.75. The company has a market capitalization of $17.03 million, a price-to-earnings ratio of -0.26 and a beta of 1.55. Carisma Therapeutics has a 52-week low of $0.38 and a 52-week high of $2.67. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CARM shares. BTIG Research downgraded shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. Robert W. Baird lowered shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the company from $10.00 to $1.00 in a research note on Thursday, December 12th. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Carisma Therapeutics in a research report on Monday, January 13th. Finally, Evercore ISI reissued an “in-line” rating and issued a $0.70 price objective (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Carisma Therapeutics currently has an average rating of “Hold” and an average price target of $4.94.

Institutional Investors Weigh In On Carisma Therapeutics

Several hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its position in shares of Carisma Therapeutics by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock worth $97,000 after purchasing an additional 24,600 shares in the last quarter. Barclays PLC boosted its stake in shares of Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares during the period. Finally, Wexford Capital LP grew its holdings in shares of Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after acquiring an additional 15,000 shares in the last quarter. 44.27% of the stock is owned by hedge funds and other institutional investors.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.